清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.

肝细胞癌 医学 内科学 脂肪肝 危险系数 荟萃分析 胃肠病学 癌 优势比 肿瘤科
作者
Darren Jun Hao Tan,Cheng Han Ng,Snow Yunni Lin,Xin Hui Pan,Phoebe Tay,Wen Hui Lim,Margaret Teng,Nicholas Syn,Grace Lim,Jie Ning Yong,Jingxuan Quek,Jieling Xiao,Yock Young Dan,Mohammad Shadab Siddiqui,Arun J Sanyal,Mark D Muthiah,Rohit Loomba,Daniel Q Huang
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (4): 521-530
标识
DOI:10.1016/s1470-2045(22)00078-x
摘要

The clinical presentation and outcomes of non-alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular carcinoma due to other causes. We aimed to establish the prevalence, clinical features, surveillance rates, treatment allocation, and outcomes of NAFLD-related hepatocellular carcinoma.In this systematic review and meta-analysis, we searched MEDLINE and Embase from inception until Jan 17, 2022, for articles in English that compared clinical features, and outcomes of NAFLD-related hepatocellular carcinoma versus hepatocellular carcinoma due to other causes. We included cross-sectional and longitudinal observational studies and excluded paediatric studies. Study-level data were extracted from the published reports. The primary outcomes were (1) the proportion of hepatocellular carcinoma secondary to NAFLD, (2) comparison of patient and tumour characteristics of NAFLD-related hepatocellular carcinoma versus other causes, and (3) comparison of surveillance, treatment allocation, and overall and disease-free survival outcomes of NAFLD-related versus non-NAFLD-related hepatocellular carcinoma. We analysed proportional data using a generalised linear mixed model. Pairwise meta-analysis was done to obtain odds ratio (OR) or mean difference, comparing NAFLD-related with non-NAFLD-related hepatocellular carcinoma. We evaluated survival outcomes using pooled analysis of hazard ratios.Of 3631 records identified, 61 studies (done between January, 1980, and May, 2021; 94 636 patients) met inclusion criteria. Overall, the proportion of hepatocellular carcinoma cases secondary to NAFLD was 15·1% (95% CI 11·9-18·9). Patients with NAFLD-related hepatocellular carcinoma were older (p<0·0001), had higher BMI (p<0·0001), and were more likely to present with metabolic comorbidities (diabetes [p<0·0001], hypertension [p<0·0001], and hyperlipidaemia [p<0·0001]) or cardiovascular disease at presentation (p=0·0055) than patients with hepatocellular carcinoma due to other causes. They were also more likely to be non-cirrhotic (38·5%, 27·9-50·2 vs 14·6%, 8·7-23·4 for hepatocellular carcinoma due to other causes; p<0·0001). Patients with NAFLD-related hepatocellular carcinoma had larger tumour diameters (p=0·0087), were more likely to have uninodular lesions (p=0·0003), and had similar odds of Barcelona Clinic Liver Cancer stages, TNM stages, alpha fetoprotein concentration, and Eastern Cooperative Oncology Group (ECOG) performance status to patients with non-NAFLD-related hepatocellular carcinoma. A lower proportion of patients with NAFLD-related hepatocellular carcinoma underwent surveillance (32·8%, 12·0-63·7) than did patients with hepatocellular carcinoma due to other causes (55·7%, 24·0-83·3; p<0·0001). There were no significant differences in treatment allocation (curative therapy, palliative therapy, and best supportive care) between patients with NAFLD-related hepatocellular carcinoma and those with hepatocellular carcinoma due to other causes. Overall survival did not differ between the two groups (hazard ratio 1·05, 95% CI 0·92-1·20, p=0·43), but disease-free survival was longer for patients with NAFLD-related hepatocellular carcinoma (0·79, 0·63-0·99; p=0·044). There was substantial heterogeneity in most analyses (I2>75%), and all articles had low-to-moderate risk of bias.NAFLD-related hepatocellular carcinoma is associated with a higher proportion of patients without cirrhosis and lower surveillance rates than hepatocellular carcinoma due to other causes. Surveillance strategies should be developed for patients with NAFLD without cirrhosis who are at high risk of developing hepatocellular carcinoma.None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我是老大的应助被chyang采纳,获得10
2秒前
丰富的从雪完成签到,获得积分10
4秒前
7秒前
10秒前
flysky120完成签到 ,获得积分10
11秒前
chyang发布了新的文献求助10
13秒前
威武妙柏完成签到,获得积分10
14秒前
光亮靳完成签到,获得积分10
24秒前
xuxu213发布了新的文献求助10
27秒前
33秒前
50秒前
54秒前
复杂的醉山完成签到,获得积分10
59秒前
tuimao发布了新的文献求助10
59秒前
赘婿的应助被tuimao采纳,获得10
1分钟前
高高的玉兰完成签到,获得积分10
1分钟前
星辰大海的应助被兰斯洛特117采纳,获得10
1分钟前
kiki完成签到,获得积分10
1分钟前
灿的完成签到,获得积分10
1分钟前
靓丽凌珍完成签到,获得积分10
1分钟前
WQY发布了新的文献求助10
1分钟前
专注寒蕾完成签到,获得积分10
2分钟前
2分钟前
灿烂而孤独的八戒完成签到 ,获得积分0
2分钟前
懵懂的小之完成签到,获得积分10
2分钟前
2分钟前
落后的山槐完成签到,获得积分10
2分钟前
2分钟前
笨小孩发布了新的文献求助30
2分钟前
1437594843完成签到 ,获得积分10
2分钟前
顺利的雅旋完成签到,获得积分10
2分钟前
Maestro_S的应助被科研通管家采纳,获得30
2分钟前
2分钟前
迷你的金鱼完成签到,获得积分10
2分钟前
甜美的冬天完成签到,获得积分10
2分钟前
玛卡巴卡爱吃饭完成签到 ,获得积分0
2分钟前
金秋完成签到,获得积分0
2分钟前
包容大地完成签到,获得积分10
3分钟前
重要盼易完成签到,获得积分10
3分钟前
兴奋雅香完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173198
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780496
捐赠科研通 7767332
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555730
邀请新用户注册赠送积分活动 2476688